Fig. 2: 4T-Trap effectively represses TGF-β signalling in lymph node CD4+ T cells. | Nature

Fig. 2: 4T-Trap effectively represses TGF-β signalling in lymph node CD4+ T cells.

From: Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells

Fig. 2

a, Schematic of antibody structures for 4T-Trap, TGF-β-Τrap, anti-CD4 and mGO53. b, Surface plasmon resonance sensorgrams of 4T-Trap and anti-CD4 binding to immobilized CD4 (left) as well as 4T-Trap and anti-TGF-β binding to immobilized TGF-β1 (right). RU, response unit. c, ELISA to assess 4T-Trap, TGF-β-Τrap, anti-CD4 and mGO53 binding to CD4, TGF-β1 or both molecules. Optical density (OD) was detected at 450 nm. d, Inhibition of TGF-β signalling after treatment with the indicated antibodies in HEK293 cells expressing human CD4 (293-hCD4) cells transfected with a TGF-β–SMAD firefly luciferase reporter plasmid (SBE-Luc) and a pRL-TK Renilla luciferase reporter plasmid. RLU, relative unit of normalized firefly luciferase activity to Renilla luciferase activity. e, Flow cytometry analyses of pSMAD2 performed on resting or activated CD4+ T cells from the tumour-draining lymph nodes of mice treated with the indicated antibodies. CD4+ T cells were left untreated (resting) or activated with phorbol acetate and ionomycin for 4 h (activated) before staining for pSMAD2. f, Representative immunofluorescence of CD4 (white) and biotin (red) in the tumour-draining lymph nodes of mice treated with the indicated antibodies. Scale bars, 10 μm. Data are representative of two (b) or three independent experiments (cf).

Source data

Back to article page